Methamphetamine exposure combined with HIV-1 disease or gp120 expression: Comparison of learning and executive functions in humans and mice

Neuropsychopharmacology

Volumn 40, Issue 8, 2015, Pages 1899-1909

  Kesby, James P ^a   Heaton, Robert K ^a   Young, Jared W ^a,b   Umlauf, Anya ^a   Woods, Steven P ^a   Letendre, Scott L ^a   Markou, Athina ^a   Grant, Igor ^a   Semenova, Svetlana ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120; METHAMPHETAMINE; SODIUM CHLORIDE; CENTRAL STIMULANT AGENT; GLIAL FIBRILLARY ACIDIC PROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENTION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EXPOSURE; EXECUTIVE FUNCTION; EXPERIMENTAL COGNITIVE TEST; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION SENSITIVITY; LEARNING; LEARNING DISORDER; MAJOR CLINICAL STUDY; MALE; MENTAL TASK; METHAMPHETAMINE DEPENDENCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; COGNITION DISORDERS; COMPLICATION; DOSE RESPONSE; DRUG DEPENDENCE; DRUG EFFECTS; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEARNING DISORDERS; METABOLISM; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; NONPARAMETRIC TEST; PHYSIOLOGY; TRANSGENIC MOUSE; YOUNG ADULT;

ADULT; ANIMALS; ATTENTION; CENTRAL NERVOUS SYSTEM STIMULANTS; COGNITION DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXECUTIVE FUNCTION; GLIAL FIBRILLARY ACIDIC PROTEIN; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HUMANS; LEARNING DISORDERS; METHAMPHETAMINE; MICE; MICE, TRANSGENIC; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; REVERSAL LEARNING; STATISTICS, NONPARAMETRIC; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 84930820972     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2015.39     Document Type: Article

References (57)

1. Achim CL, Adame A, Dumaop W, Everall IP, Masliah E (2009). Increased accumulation of intraneuronal amyloid b in HIVinfected patients. J Neuroimmune Pharm 4: 190-199.
2. Anderson SW, Tranel D (2002). Neuropsychological consequences of dysfunction in the human dorsolateral prefrontal cortex. In: Grafman J (ed). The Frontal Lobes, 2nd edn. Elsevier: Amsterdam. Vol 7, pp 145.
3. Andreollo NA, Santos EF, Araujo MR, Lopes LR (2012). Rat's age versus human's age: what is the relationship? Arq Bras Cir Dig 25: 49-51.
4. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M et al (2007). Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69: 1789-1799.
5. Aylward EH, Henderer JD, McArthur JC, Brettschneider PD, Harris GJ, Barta PE et al (1993). Reduced basal ganglia volume in HIV-1 associated dementia: results from quantitative neuroimaging. Neurology 43: 2099-2104.
6. Birrell JM, Brown VJ (2000). Medial frontal cortex mediates perceptual attentional set shifting in the rat. J Neurosci 20: 4320-4324.
7. Bousman CA, ChernerM, Glatt SJ, Atkinson JH, Grant I, TsuangMT et al (2010). Impact of COMT Val158Met on executive functioning in the context of HIV and methamphetamine. Neurobehav HIV Med 2010: 1-11.
8. Carey AN, Sypek EI, Singh HD, Kaufman MJ, McLaughlin JP (2012). Expression of HIV-Tat protein is associated with learning and memory deficits in the mouse. Behav Brain Res 229: 48-56.
9. Carey CL, Woods SP, Gonzalez R, Conover E, Marcotte TD, Grant I et al (2004). Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. J Clin Exp Neuropsychol 26: 307-319.
10. Carrico AW (2011). Substance use and HIV disease progression in the HAART era: implications for the primary prevention of HIV. Life Sci 88: 940-947.
11. Chana G, Everall IP, Crews L, Langford D, Adame A, Grant I et al (2006). Cognitive deficits and degeneration of interneurons in HIV+ methamphetamine users. Neurology 67: 1486-1489.
12. Chang L, Ernst T, Speck O, Grob CS (2005). Additive effects of HIV and chronic methamphetamine use on brain metabolite abnormalities. Am J Psychiatry 162: 361-369.
13. Chompre G, Cruz E, Maldonado L, Rivera-Amill V, Porter JT, Noel RJ (2013). Astrocytic expression of HIV-1 Nef impairs spatial and recognition memory. Neurobiol Dis 49: 128-136.
14. D'Hooge R, Franck F, Mucke L, De Deyn PP (1999). Age-related behavioural deficits in transgenic mice expressing the HIV-1 coat protein gp120. Eur J Neurosci 11: 4398-4402.
15. Der-Avakian A, D'Souza MS, Pizzagalli DA, Markou A (2013). Assessment of reward responsiveness in the response bias probabilistic reward task in rats: implications for cross-species translational research. Transl Psychiatry 3: e297.
16. Eddleston M, Mucke L (1993). Molecular profile of reactive astrocytes: implications for their role in neurological disease. Neuroscience 54: 15-36.
17. Fernandes SP, Edwards TM, Ng KT, Robinson SR (2007). HIV-1 protein gp120 rapidly impairs memory in chicks by interrupting the glutamate-glutamine cycle. Neurobiol Learn Mem 87: 1-8.
18. Gupta S, Bousman CA, Chana G, Cherner M, Heaton RK, Deutsch R et al (2011). Dopamine receptor D3 genetic polymorphism (rs6280TC) is associated with rates of cognitive impairment in methamphetamine-dependent men with HIV: preliminary findings. J Neurovirol 17: 239-247.
19. Hart CL, Marvin CB, Silver R, Smith EE (2012). Is cognitive functioning impaired in methamphetamine users? a critical review. Neuropsychopharmacology 37: 586-608.
20. Heaton RK, Clifford DB, Franklin DRJ, Woods SP, Ake C, Vaida F et al (2010). HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 75: 2087-2096.
21. Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, LeBlanc S et al (2011). HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 17: 3-16.
22. Heaton RK, Grant I, Butters N, White DA, Kirson D, Atkinson JH et al (1995). The HNRC 500: neuropsychology of HIV infection at different disease stages. J Int Neuropsychol Soc 1: 231-251.
23. Heaton RK, Marcotte TD, Mindt MR, Sadek J, Moore DJ, Bentley H et al (2004). The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc 10: 317-331.
24. Henry BL, Geyer MA, Buell M, Perry W, Young JW, Minassian A (2013). Behavioral effects of chronic methamphetamine treatment in HIV-1 gp120 transgenic mice. Behav Brain Res 236: 210-220.
25. Hestad K, McArthur JH, Dalpan GJ, Selnes OA, Nancesproson TE, Aylward E et al (1993). Regional brain atrophy in HIV-1 infection: association with specific neuropsychological testperformance. Acta Neurol Scand 88: 112-118.
26. Hoefer MM, Sanchez AB, Maung R, de Rozieres CM, Catalan IC, Dowling CC et al (2014). Combination of methamphetamine and HIV-1 gp120 causes distinct long-term alterations of behavior, gene expression, and injury in the central nervous system. Exp Neurol 263C: 221-234.
27. Hu SX, Sheng WS, Lokensgard JR, Peterson PK, Rock RB (2009). Preferential sensitivity of human dopaminergic neurons to gp120-induced oxidative damage. J Neurovirol 15: 401-410.
28. Jaeger LB, Nath A (2012). Modeling HIV-associated neurocognitive disorders in mice: new approaches in the changing face of HIV neuropathogenesis. Dis Model Mech 5: 313-322.
29. Kesby JP, Hubbard DT, Markou A, Semenova S (2014a). Expression of HIV gp120 protein increases sensitivity to the rewarding properties of methamphetamine in mice. Addict Biol 19: 593-605.
30. Kesby JP, Markou A, Semenova STMARC (2014b). Cognitive deficits associated with combined HIV gp120 expression and chronic methamphetamine exposure in mice. Eur Neuropsychopharm 25: 141-150.
31. Kieburtz K, Ketonen L, Cox C, Grossman H, Holloway R, Booth H et al (1996). Cognitive performance and regional brain volume in human immunodeficiency virus type 1 infection. Arch Neurol 53: 155-158.
32. Kim S, Jeneson A, van der Horst AS, Frascino JC, Hopkins RO, Squire LR (2011). Memory, visual discrimination performance, and the human hippocampus. J Neurosci 31: 2624-2629.
33. Kumar AM, Fernandez JB, Singer EJ, Commins D, Waldrop-Valverde D, Ownby RL et al (2009). Human immunodeficiency virus type 1 in the central nervous system leads to decreased dopamine in different regions of postmortem human brains. J Neurovirol 15: 257-274.
34. Langford D, Adame A, Grigorian A, Grant I, McCutchan JA, Ellis RJ et al (2003). Patterns of selective neuronal damage in methamphetamine-user AIDS Patients. J Acquir Immune Defic Syndr 34: 467-474.
35. Leeson VC, Robbins TW, Matheson E, Hutton SB, Ron MA, Barnes TRE et al (2009). Discrimination learning, reversal, and set-shifting in first-episode schizophrenia: stability over six years and specific associations with medication type and disorganization syndrome. Biol Psychiatry 66: 586-593.
36. Leon WC, Bruno MA, Allard S, Nader K, Cuello AC (2010). Engagement of the PFC in consolidation and recall of recent spatial memory. Learn Mem 17: 297-305.
37. Lindl KA, Marks DR, Kolson DL, Jordan-Sciutto KL (2010). HIVassociated neurocognitive disorder: pathogenesis and therapeutic opportunities. J Neuroimmune Pharm 5: 294-309.
38. Mark KA, Soghomonian JJ, Yamamoto BK (2004). High-dose methamphetamine acutely activates the striatonigral pathway to increase striatal glutamate and mediate long-term dopamine toxicity. J Neurosci 24: 11449-11456.
39. Marquez C, Mitchell SJ, Hare CB, John M, Klausner JD (2009). Methamphetamine use, sexual activity, patient-provider communication, and medication adherence among HIV-infected patients in care, San Francisco 2004-2006. AIDS Care 21: 575-582.
40. Marquine MJ, Iudicello JE, Morgan EE, Brown GG, Letendre SL, Ellis RJ et al (2014). "Frontal systems" behaviors in comorbid human immunodeficiency virus infection and methamphetamine dependency. Psychiatry Res 215: 208-216.
41. Norman MA, Moore DJ, Taylor M, Franklin D, Cysique L, Ake C et al (2011). Demographically corrected norms for African Americans and Caucasians on the Hopkins Verbal Learning Test-Revised, Brief Visuospatial Memory Test-Revised, Stroop Color and Word Test, and Wisconsin Card Sorting Test 64-Card Version. J Clin Exp Neuropsychol 33: 793-804.
42. Panenka WJ, Procyshyn RM, Lecomte T, MacEwan GW, Flynn SW, Honer WG et al (2013). Methamphetamine use: a comprehensive review of molecular, preclinical and clinical findings. Drug Alcohol Depen 129: 167-179.
43. Purohit V, Rapaka R, Shurtleff D (2011). Drugs of abuse, dopamine, and HIV-associated neurocognitive disorders/HIV-associated dementia. Mol Neurobiol 44: 102-110.
44. Rippeth JD, Heaton RK, Carey CL, Marcotte TD, Moore DJ, Gonzalez R et al (2004). Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons. J Int Neuropsychol Soc 10: 1-14.
45. Roberts AJ, Maung R, Sejbuk NE, Ake C, Kaul M (2010). Alteration of methamphetamine-induced stereotypic behaviour in transgenic mice expressing HIV-1 envelope protein gp120 J Neurosci Methods 186: 222-225.
46. Santosuosso M, Righi E, Lindstrom V, Leblanc PR, Poznansky MC (2009). HIV-1 envelope protein gp120 is present at high concentrations in secondary lymphoid organs of individuals with chronic HIV-1 infection. J Infect Dis 200: 1050-1053.
47. Scott JC, Woods SP, Matt GE, Meyer RA, Heaton RK, Atkinson JH et al (2007). Neurocognitive effects of methamphetamine: a critical review and meta-analysis. Neuropsychol Rev 17: 275-297.
48. Segal DS, Kuczenski R (1997). An escalating dose "binge" model of amphetamine psychosis: behavioral and neurochemical characteristics. J Neurosci 17: 2551-2566.
49. Steinberg EE, Keiflin R, Boivin JR, Witten IB, Deisseroth K, Janak PH (2013). A causal link between prediction errors, dopamine neurons and learning. Nat Neurosci. 16: 966-973.
50. Toggas SM, Masliah E, Rockenstein EM, Rall GF, Abraham CR, Mucke L (1994). Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. Nature 367: 188-193.
51. Turchan J, Anderson C, Hauser KF, Sun QM, Zhang JY, Liu Y et al (2001). Estrogen protects against the synergistic toxicity by HIV proteins, methamphetamine and cocaine. BMC Neurosci 2: 3
52. Vitkovic L, daCunha A (1995). Role for astrocytosis in HIV-1-associated dementia. In: Oldstone MBA, Vitkovic L (eds). HIV and Dementia. Springer-Verlag: Berlin. Vol 202, pp 105-116.
53. Weber E, Blackstone K, Woods SP (2013). Cognitive neurorehabilitation of HIV-associated neurocognitive disorders: a qualitative review and call to action. Neuropsychol Rev 23: 81-98.
54. Woods SP, Scott JC, Fields JA, Poquette A, Troster AI (2008). Executive dysfunction and neuropsychiatric symptoms predict lower health status in essential tremor. Cogn Behav Neurol 21: 28-33.
55. Young JW, Geyer MA, Rissling AJ, Sharp RF, Eyler LT, Asgaard GL et al (2013). Reverse translation of the rodent 5C-CPT reveals that the impaired attention of people with schizophrenia is similar to scopolamine-induced deficits in mice. Transl Psychiatry 3: e324.
56. Young JW, Minassian A, Paulus MP, Geyer MA, Perry W (2007). A reverse-translational approach to bipolar disorder: rodent and human studies in the Behavioral Pattern Monitor. Neurosci Biobehav Rev 31: 882-896.
57. Young JW, Powell SB, Geyer MA, Jeste DV, Risbrough VB (2010). The mouse attentional-set-shifting task: a method for assaying successful cognitive aging? Cogn Affect Behav Neurosci 10: 243-251.